Keywords
How to Cite
Abstract
Aim is the immunocytochemical study of the expression of thyroid peroxidase and thyroglobulin in the puncture material of radioiodine-resistant and radioiodine-sensitive metastatic papillary thyroid carcinoma, to ascertain the possibility of their joint use as markers of pre-operative prediction of the effectiveness of radioiodine-therapy. Material and methods. Immunocytochemical studies using monoclonal antibodies against thyroglobulin and
thyroid peroxidase were performed on the material of Fine Needle Aspiration Biopsy of 104 metastases detected after thyroidectomy and radioiodine therapy (79 — radioiodine-resistant, 25 — radioiodineuptake). The statistical analysis was performed using the nonparametric Mana-Whitney method in the Statistica 11 program. Results. A very significant difference was found at a significance level of p<0.001 between percent of thyroid cells expressing thyroid
peroxidase and thyroglobulin between radioiodine-resistant and radioiodine-sensitive papillary thyroid metastases. The efficacy of radioiodine therapy is different in patients with different expression of thyroid peroxidase. Intermediate values of the percentage of cells with the expression of thyroid peroxidase although they cause moderate accumulation of radioiodine, but may not be sufficient for successful radioiodinetherapy. The consistent determination of
expression of thyroglobulin and thyroid peroxidase in the postoperative of the thyroid papillary cancers metastasesa increases the accuracy of prediction of their radioiodine resistance, especially when detecting a questionable percentage of cells with thyroid peroxidase. In the absence of an expression of thyroglobulin in papillary thyroid carcinoma metastases found in the postoperative period, it is impossible to exclude a zero level of thyroglobulin in serum,
even in the presence of metastases. Therefore, it is not necessary to have a comprehensive personalized approach to such patients. Conclusions. A new method of preoperative prediction of the effectiveness of radioiodine therapy based on immunocytochemical determination of thyroid peroxidase and thyroglobulin expression in punctates of papillary thyroid cancer metastases detected after thyroidectomy and radioiodine was proposed.
References
2. Busaidy N, Cabanillas M. Differentiated Thyroid Cancer: Management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012;2012:618985.
3. Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, Wirth L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 2012; 7 (5): 541-54.
4. Degroot LJ, Niepomniszcze H. Biosynthesis of thyroid hormone: basic an clinical aspects. Metabolism. 1977; 26(6): 665-718.
5. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology. 2004;145(6):2865-75.
6. Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA, Smit JWA. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2006; 154(4): 525-31.
7. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131 I uptake. Clin Endocrinol. 2008; 68(1):108-16.
8. Huang M, Batra RK, Kogai T, Lin YQ, Hershman JM, Lichtenstein A, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 2001;8(8):612-8.
9. Caballero Y, López-Tomassetti EM, Favre J, Santana JR, Cabrera JJ, Hernández JR. The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer — a long-term follow-up study. Thyroid Res. 2015; 8(12).
10. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid. 2007 Jul;17(7):639-46.
11. Bätge B, Dralle H, Padberg B, von Herbay B, Schröder S. Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: A clinicomorphological study of 62 recurrent or metastatic tumours. Vichows Archiv A Pathol Anat. 1992, 421 (6):521-6.
12. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 2007;142(8):717-29.
13. Dralle H, Schwarzrock R, Lang W, Böcker W, Ziegler H, Schröder S, Geerlings H. Comparison of histology and immunohistochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta Endocrinol (Copenh). 1985;108(4):504-10.
14. Wang C, Zhang X, Li H, Li X, Lin Y. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis. PLoSOne. 2017; 12(7): e0179664.